Extremely Rare Prostate Metastasis From Rectal Carcinoma Detected on ⁶⁸Ga-FAPI PET/CT.

Clin Nucl MedApr 27, 2026 (epub)
Case ReportOncology (Medical)Urology

Parth Bambhroliya, T Kishan Subudhi, Srijani Mandal et al.

✦ AI-curated · Sources linked

Case in brief

A 52-year-old man with a history of rectal adenocarcinoma presented with lower urinary tract symptoms and rising serum creatinine levels. Despite normal PSA levels and no local recurrence on colonoscopy, elevated CEA levels prompted further investigation. Whole-body ⁶⁸Ga-FAPI PET/CT showed diffuse tracer uptake in the prostate, and a biopsy confirmed metastatic adenocarcinoma from the rectal primary.

Diagnostic / clinical pearl

This case highlights the potential for prostate metastasis from colorectal adenocarcinoma, which is typically due to local extension rather than distant spread.

Why it matters

The use of ⁶⁸Ga-FAPI PET/CT may enhance the detection of unusual metastatic patterns in patients with a history of colorectal cancer.

Source

PubMed · PMID 42523055

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.